EcoDrugPlus

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSPFOG00000000684
Gene Symbol: LOC103152501
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSPFOG00000007827
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSPFOG00000011264
Gene Symbol: P2RX3B
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSPFOG00000020261
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSPFOG00000024570
Gene Symbol: P2RY12
1 Cross references
180 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSPFOG00000002438
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSPFOG00000011890
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSPFOG00000001938
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSPFOG00000015545
Gene Symbol: RIPK1L
1 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPFOG00000013837
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPFOG00000002861
Gene Symbol: RAMP1
1 Cross references
191 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3

Ensembl ID : ENSPFOG00000001978
Gene Symbol: LOC103143265
2 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).